IDEAYA Biosciences (IDYA) to Release Earnings on Thursday

IDEAYA Biosciences (NASDAQ:IDYA) will likely be posting its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect IDEAYA Biosciences to post earnings of ($1.03) per share and revenue of $5.9460 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 13, 2026 at 12:30 PM ET.

IDEAYA Biosciences (NASDAQ:IDYA) last released its earnings results on Tuesday, November 4th. The company reported $1.33 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $1.45. The business had revenue of $207.83 million during the quarter, compared to analysts’ expectations of $59.98 million. On average, analysts expect IDEAYA Biosciences to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

IDEAYA Biosciences Trading Down 2.8%

Shares of IDYA opened at $33.28 on Thursday. The firm has a fifty day moving average price of $34.91 and a 200-day moving average price of $29.92. The firm has a market capitalization of $2.92 billion, a P/E ratio of -17.89 and a beta of 0.10. IDEAYA Biosciences has a 12-month low of $13.45 and a 12-month high of $39.28.

Institutional Investors Weigh In On IDEAYA Biosciences

Several institutional investors have recently bought and sold shares of the company. Daiwa Securities Group Inc. increased its position in shares of IDEAYA Biosciences by 16.1% during the second quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock worth $66,000 after purchasing an additional 436 shares in the last quarter. Osaic Holdings Inc. increased its holdings in shares of IDEAYA Biosciences by 59.1% during the second quarter. Osaic Holdings Inc. now owns 7,443 shares of the company’s stock valued at $148,000 after acquiring an additional 2,764 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new stake in IDEAYA Biosciences in the 3rd quarter worth approximately $233,000. Russell Investments Group Ltd. increased its stake in IDEAYA Biosciences by 790.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 9,207 shares of the company’s stock valued at $251,000 after purchasing an additional 8,173 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in shares of IDEAYA Biosciences by 677.3% during the second quarter. Tower Research Capital LLC TRC now owns 9,538 shares of the company’s stock worth $200,000 after buying an additional 8,311 shares during the period. 98.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have issued reports on IDYA. Truist Financial boosted their price objective on shares of IDEAYA Biosciences from $59.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. BTIG Research reaffirmed a “buy” rating and set a $62.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, October 21st. New Street Research set a $30.00 price objective on IDEAYA Biosciences in a research note on Tuesday, October 21st. The Goldman Sachs Group lifted their target price on IDEAYA Biosciences from $27.00 to $30.00 and gave the company a “neutral” rating in a research report on Tuesday, October 21st. Finally, JPMorgan Chase & Co. increased their target price on shares of IDEAYA Biosciences from $74.00 to $79.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Fifteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $46.60.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.